ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial

▤ Summary

AstraZeneca reported subgroup results from its Phase III CARES program for anselamimab in light chain amyloidosis. The therapy missed the primary endpoint in the overall population, but it showed meaningful benefit in patients with kappa light chain isotype. In the prespecified subgroup, the drug reduced all-cause mortality and cardiovascular hospitalizations compared with placebo. The article also places the data in context by noting AstraZeneca’s acquisition of Alexion and the broader competitive landscape in AL amyloidosis.

▦ Linked Companies